Skip to main content
SpringerLink
Log in

Management of Factor VIII Inhibitors

  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

The development of inhibitory alloantibodies to factor VIII (FVIII) is a major complication of clotting factor replacement therapy for hemophilia A. Inhibitor development compromises effective hemostasis management in affected individuals and results in higher morbidity and costs of care compared with hemophilic individuals without anti-FVIII antibodies. The therapeutic approach to the management of bleeding in the presence of low- and high-titer inhibitors is founded on the principles of either saturating antibody with excess FVIII or bypassing the FVIII requirement altogether. Although spontaneous antibody disappearance does occur, immune tolerance is often required for antibody eradication. Studies aimed at optimizing this treatment approach and developing newer strategies for inhibitor prevention are ongoing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. DiMichele DM, Neufeld EJ. Hemophilia: a new approach to an old disease. Hematol Oncol Clin North Am. 1998;12:1315–1344.

    Article  CAS  PubMed  Google Scholar 

  2. Oldenburg J, Brackmann HH, Schwaab R. Risk factors for inhibitor development in hemophilia A. Haematologica. 2000;85:7–13.

    CAS  PubMed  Google Scholar 

  3. Peerlinck K, Jacquemin M. Characterization of inhibitors in congenital hemophilia. In: Rodriguez-Merchan EC, Lee CA, eds. Inhibitors in Patients with Haemophilia. Oxford, UK: Blackwell; 2002:9–13.

    Chapter  Google Scholar 

  4. Lacroix-Desmazes S, Sooryanarayana, Moreau A, Kazatchkine MD, Kaveri SV. Factor VIII inhibitor with catalytic activity towards factor VIII. Haematologica. 2000;85(suppl):89–92.

    Google Scholar 

  5. Arai M, Scandella D, Hoyer LW. Molecular basis of factor VIII inhibition by human antibodies: antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest. 1989;83:1978–1984.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Shima M, Scandella D, Yoshioka A, et al. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost. 1993;69:240–246.

    Article  CAS  Google Scholar 

  7. Kazatchkine MD, Sultan Y, Burton-Kee EJ, Mowbray JF. Circulating immune complexes containing anti-FVIII antibodies in multitransfused patients with hemophilia A. Clin Exp Immunol. 1980;39:315–320.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet. 1992;339:594–598.

    Article  CAS  PubMed  Google Scholar 

  9. Brown DL, Bray GL, Scharrer I. Transient inhibitors in patients with hemophilia A [abstract]. Thromb Haemost. 1999;82(suppl):573. Abstract 1804.

    Google Scholar 

  10. Bray GL, Gomperts ED, Courter S, et al. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy and inhibitor risk in previously untreated individuals with hemophilia A.The Recombinate Study Group. Blood. 1994;83:2428–2435.

    CAS  PubMed  Google Scholar 

  11. Lusher JM, Spira J, Rodriguez D. A four-year update of safety and efficacy of an albumin-free formulated B-domain deleted factor VIII (BBD rFVIII, rVIIIISQ) in previously untreated severe hemophilia A patients. Thromb Haemost. 1999;82:1493.

    Google Scholar 

  12. Giles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci. 1998;19:139–148.

    Article  CAS  PubMed  Google Scholar 

  13. Kreuz W, Ettingshausen CE, Auerswald G, et al, for the GTH PUP Study Group. Epidemiology of inhibitors and current treatment strategies. Haematologica. 2003;88:EREP04.

    PubMed  Google Scholar 

  14. Kasper CK, Aledort L, Aronson D, et al. Proceedings: a more uniform measurement of factor VIII inhibitors [letter]. Thromb Diath Haemorrh. 1975;34:612.

    CAS  PubMed  Google Scholar 

  15. Verbruggen B, Novakova I, Wessels H, et al. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost. 1995;73:247–251.

    Article  CAS  Google Scholar 

  16. Paisley S, Wight J, Currie E, Knight C. The management of inhibitors in hemophilia A: introduction and systematic review of current practice. Haemophilia. 2003;9:405–417.

    Article  CAS  PubMed  Google Scholar 

  17. White GC 2nd, Rosendaal F, Aledort L, Lusher JM, Rothschild C, Ingerslev J, for the Factor VIII and Factor IX Subcommittee. Definitions in hemophilia: recommendation of the scientific subcommittee on factor VIII and factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Thromb Haemost. 2001;85:560.

    Article  CAS  PubMed  Google Scholar 

  18. Fulcher CA. Immunochemistry of factor VIII:C inhibitor antibodies. Am J Med. 1991;91:6S-8S.

    Article  CAS  PubMed  Google Scholar 

  19. Gilles JG, Arnout J, Vermylen J, Saint-Remy JM. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood. 1993;82:2452–2461.

    CAS  PubMed  Google Scholar 

  20. Saenko EL, Ananyeva NM, Kouiavskaia DV, et al. Haemophilia A: effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their action. Haemophilia. 2002;8:1–11.

    Article  CAS  PubMed  Google Scholar 

  21. Fulcher CA, De Graaf Mahoney S, Roberts JR, Kasper CK, Zimmerman TS. Localization of human factor VIII epitopes to two polypeptide fragments. Proc Natl Acad Sci U S A. 1985;82:7728–7732.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Jacquemin MG, Saint-Remy JM. Factor VIII alloantibodies in hemophilia. Curr Opin Hematol. 2004;11:146–150.

    Article  CAS  PubMed  Google Scholar 

  23. Kreuz W, Ettingshausen CE, Zyschka A, et al. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin Thromb Hemost. 2002;28:285–290.

    Article  CAS  PubMed  Google Scholar 

  24. Oldenberg J, Tuddenham E. Genetic basis of inhibitor development in severe hemophilia A and B. In: Rodriguez-Merchan EC, Lee CA, eds. Inhibitors in Patients with Haemophilia. Oxford, UK: Blackwell; 2002:21–26.

    Chapter  Google Scholar 

  25. Astermark J, Berntorp E, White GC, Kroner BL, for the MIBS Study Group. The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia. 2001;7:267–272.

    Article  CAS  PubMed  Google Scholar 

  26. Addiego JR Jr, Kasper C, Abildgaard C, et al. Increased frequency of inhibitors in African American hemophilia A patients [abstract]. Blood. 1994;84(suppl 1):239a.

    Google Scholar 

  27. Lorenzo JI, Lopez A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe hemophilia: the importance of patient age. Br J Haematol. 2001;113:600–603.

    Article  CAS  PubMed  Google Scholar 

  28. Sharathkumar A, Lillicrap D, Blanchette VS, et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost. 2003;1:1228–1236.

    Article  CAS  PubMed  Google Scholar 

  29. Knobel KE, Sjorin E, Tengborn LI, Petrini P, Ljung RC. Inhibitors in the Swedish population with severe haemophilia A and B: a 20- year survey. Acta Paediatr. 2002;91:910–914.

    Article  Google Scholar 

  30. Rothschild C, Goudemand J, Demiguel V, Lambert T, Calvez T. Effect of type of treatment (recombinant vs. plasmatic) on FVIII inhibitor incidence according to known risk cofactors in previously untreated severe hemophilia A patients (PUPs) [abstract]. J Thromb Haemost. 2003;1(suppl). Abstract OC215.

    Google Scholar 

  31. Behrmann M, Pasi J, Saint-Remy JM, Kotitschke R, Kloft M. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a hemophilia A mouse model. Thromb Haemost. 2002;88:221–229.

    Article  CAS  PubMed  Google Scholar 

  32. Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX: Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Thromb Haemost. 1991;66:384–386.

    Article  CAS  Google Scholar 

  33. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood. 1995;86:983–988.

    CAS  PubMed  Google Scholar 

  34. Schulman S. Continuous infusion. Haemophilia. 2003;9:368–375.

    Article  CAS  PubMed  Google Scholar 

  35. Lusher JM, Blatt PM, Penner JA, et al. Autoplex versus Proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood. 1983;62:1135–1138.

    CAS  PubMed  Google Scholar 

  36. Turecek PL, Varadi K, Gritsch H, Schwarz HP. FEIBA: mode of action. Haemophilia. 2004;10(suppl 2):3–9.

    Article  CAS  PubMed  Google Scholar 

  37. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost. 1997;77:1113–1119.

    Article  CAS  Google Scholar 

  38. Hilgartner MW, Makipernaa A, DiMichele DM. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia. 2003;9:261–268.

    Article  CAS  PubMed  Google Scholar 

  39. Brackmann HH, Oldenberg J, Schwaab R. Immune tolerance for the treatment of FVIII inhibitors: twenty years of the Bonn protocol. Vox Sang. 1996;70(suppl 1):30–35.

    Article  PubMed  Google Scholar 

  40. Hoffman M, Monroe DM III. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol. 2001;38:6–9.

    Article  CAS  PubMed  Google Scholar 

  41. Lisman T, Mosnier LO, Lambert T, et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood. 2002;99:175–179.

    Article  CAS  PubMed  Google Scholar 

  42. Bech RM. Recombinant factor VIIa in joint and muscle bleeding episodes. Haemostasis. 1996;26(suppl 1):135–138.

    CAS  PubMed  Google Scholar 

  43. Lusher JM, Roberts HR, Davignon G, et al. A randomized, doubleblind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors: rFVIIa Study Group. Haemophilia. 1998;4:790–798.

    Article  CAS  PubMed  Google Scholar 

  44. Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in hemophiliacs with inhibitors. Thromb Haemost. 1998;80:912–918.

    Article  CAS  PubMed  Google Scholar 

  45. Lusher JM. Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII. Blood Coagul Fibrinolysis. 2000;11(suppl 1):S45-S49.

    Article  CAS  PubMed  Google Scholar 

  46. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost. 1998;80:773–778.

    Article  CAS  PubMed  Google Scholar 

  47. Ingerslev J, Freidman D, Gastineau D, et al. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Hemostasis. 1996;26:118–123..

    CAS  Google Scholar 

  48. Schulman S, d’Oiron R, Martinowitz U, et al. Experiences with con tinuous infusion of recombinant activated factor VII. Blood Coagul Fibrinolysis. 1998;9(suppl 1):S97-S101.

    CAS  PubMed  Google Scholar 

  49. Shapiro A. Inhibitor treatment: state of the art. Semin Hematol. 2001;38:26–34.

    Article  CAS  PubMed  Google Scholar 

  50. Kenet G, Lubetsky A, Luboshitz J, Martinowitz U. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (Novo- Seven). J Thromb Haemost. 2003;1:450–455.

    Article  CAS  PubMed  Google Scholar 

  51. Hoffman M, Monroe DM 3rd. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol. 2001;38(suppl 12):6–9.

    Article  CAS  PubMed  Google Scholar 

  52. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia. 2002;8:83–90.

    Article  CAS  PubMed  Google Scholar 

  53. Ludlam CA. The evidence behind inhibitor treatment with recombinant factor VIIa. Pathophysiol Haemost Thromb. 2002;32(suppl 1):13–18.

    Article  CAS  PubMed  Google Scholar 

  54. Antovic J, Schulman S, Eelde A, Blomback M. Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A. Haemophilia. 2001;7:557–560.

    Article  CAS  PubMed  Google Scholar 

  55. Mariani G, Kroner B, and the Immune Tolerance Study Group (ITSG). Immune tolerance in haemophilia with factor VIII inhibitors: predictors of success. Haematologica. 2001;86:1186–1193.

    CAS  PubMed  Google Scholar 

  56. Jansen M, Schmaldienst S, Banyai S, et al. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol. 2001;112:91–97.

    Article  CAS  PubMed  Google Scholar 

  57. Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet. 1977;2:933.

    Article  CAS  PubMed  Google Scholar 

  58. Mariani G, Siragusa S, Kroner BL. Immune tolerance induction in hemophilia A: a review. Semin Thromb Hemost. 2003;29:69–76.

    Article  CAS  PubMed  Google Scholar 

  59. DiMichele D, Kroner B, and the Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Haematologica. 2000;85(suppl):42–44.

    Google Scholar 

  60. Mariani G, Scheibel E, Nogao T, et al. Immunetolerance as treatment of alloantibodies to factor VIII in hemophilia: the International Registry of Immunetolerance Protocols. Semin Hematol. 1994;31:62–64.

    CAS  PubMed  Google Scholar 

  61. Lenk H, and the ITT Study Group. The German Registry of immune tolerance treatment in hemophilia: 1999 update. Haematologica. 2000;85(suppl):45–47.

    CAS  PubMed  Google Scholar 

  62. DiMichele DM, Kroner B, and the North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost. 2002;87:52–57.

    Article  CAS  PubMed  Google Scholar 

  63. DiMichele DM. Immune tolerance: a synopsis of the international experience. Haemophilia. 1998;4:568–573.

    Article  CAS  Google Scholar 

  64. Kroner BL. Comparison of the International Immune Tolerance Registry and the North American Immune Tolerance Registry. Vox Sang. 1999;77(suppl 1):33–37.

    Article  PubMed  Google Scholar 

  65. Ljung R. Central venous lines in haemophilia. Haemophilia. 2003;9(suppl 1):88–93.

    Article  PubMed  Google Scholar 

  66. Hay CR, Ludlam CA, Colvin BT, et al. FVIII inhibitors in mild and moderate-severity haemophilia A: UK Haemophilia Centre Directors Organisation. Thromb Haemost. 1998;79:762–766.

    Article  CAS  PubMed  Google Scholar 

  67. Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg B, Nilsson IM. Tolerance induction using the Malmö treatment model 1982-1995. Haemophilia. 1999;5:32–39.

    Article  CAS  PubMed  Google Scholar 

  68. Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood. 2004;103:4424–4428.

    Article  CAS  PubMed  Google Scholar 

  69. Mathias M, Khair K, Hann I, Liesner R. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia. Br J Haematol. 2004;125:366–368.

    Article  PubMed  Google Scholar 

  70. Barrow RT, Healey JF, Gailani D, et al. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. Blood. 2000;95:564–568.

    CAS  PubMed  Google Scholar 

  71. Villard S, Lacroix-Desmazes S, Kieber-Emmons T, et al. Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor. Blood. 2003;102:949–952.

    Article  CAS  PubMed  Google Scholar 

  72. Reding MT, Okita DK, Diethelm-Okita BM, et al. Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII. J Thromb Haemost. 2003;1:1777–1784.

    Article  CAS  PubMed  Google Scholar 

  73. Evans GL, Morgan RA. Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A. Proc Natl Acad Sci U S A. 1998;95:5734–5739.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Berntorp E, Astermark J, Carlborg E. Immune tolerance induction and the treatment of hemophilia: Malmö protocol update. Haematologica. 2000;85(suppl):48–51.

    CAS  PubMed  Google Scholar 

  75. Freiburghaus C, Berntorp E, Eckman M, et al. Tolerance induction using the Malmo treatment model 1982-1995. Haemophilia. 1999;5:32–39.

    Article  CAS  PubMed  Google Scholar 

  76. Smith MP, Spence KJ, Waters EL, et al. Immune tolerance therapy for hemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution. Thromb Haemost. 1999;81:35–38.

    Article  CAS  PubMed  Google Scholar 

  77. Rocino A, Papa ML, Salerno E, et al. Immune tolerance induction in hemophilia A patients with high-responding inhibitors to factor VIII: experiecne at a single institution. Hemophilia. 2001;7:33–38.

    Article  CAS  Google Scholar 

  78. Mauser-Bunschoten EP, Rosendaal FR, Nieuwenhuis HK, et al. Clinical course of factor VIII inhibitors developed after exposure to a pasteurised Dutch concentrate compared to classic inhibitors in hemophilia A. Thromb Haemost. 1994;71:703–706.

    Article  CAS  Google Scholar 

  79. Gruppo RA, Valdez LP, Stout RD. Induction of immune tolerance in patients with hemophilia A and inhibitors. Am J Pediatr Hematol Oncol. 1992;14:82–87.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Donna M. DiMichele

    Present address: New York Weill Cornell Center, 525 E 68th St, P695, 10021, New York, NY, USA

Authors and Affiliations

  1. Weill Medical College of Cornell University, New York, New York, USA

    Donna M. DiMichele

Authors
  1. Donna M. DiMichele
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Donna M. DiMichele.

About this article

Cite this article

DiMichele, D.M. Management of Factor VIII Inhibitors. Int J Hematol 83, 119–125 (2006). https://doi.org/10.1532/IJH97.05129

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1532/IJH97.05129

Key words

Search

Navigation